What is the purpose of this trial?
The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease (ADAD) mutation.
Ages: 18 - 80 years
Washington University School of Medicine
Dates: 03/11/2014 - 09/30/2019
Last Updated: 11/17/2015
Study HIC#: 1308012526